This Week in Nephrology — Jun 6, 2026

Welcome to This Week in Nephrology. This week we're covering 10 notable papers, with a major focus on the expanding evidence for finerenone in chronic kidney disease, new data in glomerular disease, and important updates on risk management in advance…

This week's papers: 1. Kidney Disease: Improving Global Outcomes (KDIGO) Life Cycle of Guideline Development: Part 1: Introduction to a new series. — Kidney international 2026 2. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). — Lancet (London, England) 2026 3. Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity. — Journal of the American Society of Nephrology : JASN 2026 4. Finerenone in Persons with Chronic Kidney Disease without Diabetes. — The New England journal of medicine 2026 5. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. — JAMA 2026 6. Atrasentan in patients with IgA nephropathy (ALIGN): final 2.5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. — Lancet (London, England) 2026 7. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. — JAMA 2026 8. Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes. — JAMA 2026 9. Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges. — Lancet (London, England) 2026 10. Advances in the diagnosis and detection of chronic kidney disease. — Lancet (London, England) 2026

Listen at https://audioscholar.cc/episode/fbgn6n3fa2